Concepts (50)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuregulin-1 | 1 | 2024 | 89 | 0.230 |
Why?
|
| Survivorship | 1 | 2024 | 116 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5574 | 0.190 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 2331 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 318 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2024 | 742 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 625 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 1828 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 12033 | 0.100 |
Why?
|
| Quality of Life | 1 | 2024 | 4761 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 500 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 10708 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 690 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5257 | 0.070 |
Why?
|
| Receptor, ErbB-3 | 1 | 2024 | 126 | 0.050 |
Why?
|
| p21-Activated Kinases | 1 | 2023 | 131 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 2650 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 2399 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 318 | 0.050 |
Why?
|
| Neoplasms | 2 | 2024 | 15927 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 9039 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 126 | 0.040 |
Why?
|
| Karyopherins | 1 | 2021 | 134 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2021 | 484 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 797 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 823 | 0.040 |
Why?
|
| Mutation | 3 | 2024 | 15912 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 617 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1402 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4961 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2021 | 1691 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 961 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 481 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 1335 | 0.030 |
Why?
|
| Humans | 7 | 2024 | 270740 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2651 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3409 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2020 | 1436 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1353 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 82040 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 5231 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 90352 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 14012 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 30998 | 0.010 |
Why?
|
| Male | 2 | 2024 | 128315 | 0.010 |
Why?
|
| Female | 2 | 2024 | 148940 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2024 | 39890 | 0.010 |
Why?
|
| Aged | 1 | 2024 | 73333 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 61956 | 0.010 |
Why?
|